Anticancer Activities of Hesperidin and Hesperetin In vivo and their Potentiality against Bladder Cancer

Danijela Stanisic1, Amanda F. Costa1, Wagner J. Fávaro1,2, Ljubica Tasic1,2, Arnedea B. Seabra1,3 and Nelson Durán2,3,4,5*

1Biological Chemistry Laboratory, Institute of Chemistry, University of Campinas, Campinas, SP, Brazil
2Department of Structural and Functional Biology, Laboratory of Urogenital Carcinogenesis and Immunotherapy, University of Campinas, Campinas, SP, Brazil
3NanoBioss – Institute of Chemistry, University of Campinas, Campinas, SP, Brazil
4Nanomedicine Research Unit, Federal University of ABC, Santo André, Brazil
5Center for Natural and Human Sciences, Federal University of ABC, Santo André, SP, Brazil

Abstract

Hesperidin and its aglycone hesperetin have emerged as important anticancer natural products from orange resources, while bladder cancer has been a great treat to animals and humans in very severe forms. Bladder cancer is usually treated with extremely toxic chemotherapeutics, such as doxorubicin, cisplatin, mitomycin-C, etc., and there is as an urgent need for new chemotherapeutics for its treatment. An important strategy to minimize the toxic effects of the above cited drugs is to use co-adjuvant. Hesperidin and hesperetin have shown promising results in the suppression of various types of cancer (colon, prostate, hepatic, bladder and lung cancer), as a drug or as pro-drug and co-adjuvants. This mini-review points to the importance of flavonoids in different cancers’ treatments, with special attention on the combat of bladder cancer.

Keywords: Hesperidin; Hesperetin; Bladder cancer; Oranges; Chemotherapeutics

Introduction

Hesperidin (3’,5,7-trihydroxy-4’-methoxy flavanone-7-6-O-α-L-rhamnosyl-D-glucose) (Figure 1) is a naturally occurring flavonoid found abundantly in vegetables and fruits [1]. It is a cheap byproduct of citrus production and one of the most important bioflavonoids in sweet orange and lemon [2]. Hesperidin exhibits many beneficial effects such as anti-allergic, anti-oxidant and anti-inflammatory actions [3]. Anticarcinogenic effects in tongue, esophagus, colon and urinary bladder in rat models of carcinogenesis were reported [4].

Hesperetin (3’,5,7-trihydroxy-4’-methoxy flavanone) is also a natural flavonoid, an aglycone of hesperidin (Figure 1), which has been reported to exert similar biological activities when compared to hesperidin and interesting therapeutic value in neuropathological conditions [5].

In vivo Anticancer Activities of Hesperidin and Hesperetin

Phytochemicals derived from hesperidin have important chemoprotective roles in carcinogenesis. There are many types of cancers in which it is known that hesperidin can act effectively, such as colon cancer (adenoma and adenocarcinoma), breast cancer, melanoma, prostate cancer, hepatocellular carcinoma, and many others, as well as in metastasis reduction. It is also known that in lung, liver, breast, stomach, and colon cancer, hesperidin probably acts through the promotion of cancer cells apoptosis via multiple mechanisms [6].

Arafa et al. reported the effect of hesperidin on benzo[a]pyrene (BaP) that induced testicular toxicity in rats. The authors showed the BaP (orally administrated) diminished the testicular activities of superoxide dismutase (SOD), glutathione S-transferase (GST), and testicular glutathione (GSH) and increased malondialdehyde (MDA) contents. Hesperidin orally applied as pretreatment ameliorated all the biological and histological changes induced by BaP. As well, hesperidin had a protection effect vs. lung cancer induced by BaP in mice [7].

Saiprasad et al. reported the chemopreventive potential of hesperidin against an inducer of colon carcinogenesis (azoxymethane - AOM) in mice model. Hesperidin orally applied in mice inhibited the nuclear factor-kappa B (NF-κB) dependent inflammatory responses including inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) activation [8]. More recent studies related to elucidation of molecular mechanism indicated that hesperidin induced apoptosis and cell cycle arrest in AOM that produce mouse colon carcinogenesis via inhibiting Phosphoinositide 3-kinase/Protein kinase B (PI3K/Akt) pathway and inhibiting Aurorora-A and Akt mediated GSK-3β/β-

Figure 1: Bioflavonoids from oranges are potentially great adjuvants in anticancer treatment and, in bladder cancer therapy minimize toxic chemotherapeutics effects. Illustrated are the structures of already tested bioflavonoids in vivo. We emphasize the positive effects of hesperetin and hesperidin.
cancer, the next sections present and discuss the recent progress on the uses chemotherapeutic regimens to combat bladder cancer and the potentiality against Bladder Cancer. In vivo and their in the induction of colon cancer model rats by 1,2-dimethylhydrazine (DMH) [21]. Also, it inhibited growth of aromatase-expressing MCF-7 tumor in ovariectomized athymic mice by decreasing cyclin D1, CDK4, and Bcl-x(L), when upregulating the level of p57KIP1 [22].

Hesperetin treatment of C6 gliomas caused a marked decrease in the tumor permeability and edema and increased expression of tight junction-associated proteins. Hesperetin treatment also downregulated the HIF-1a/VEGF/VEGFR2 pathway and it was concluded that hesperetin possesses anti-tumor properties in implanted C6 glioma cells in rats [23].

The combination of hesperetin and nanomaterials represents a new strategy to treat cancer cells. In this sense, hesperetin conjugated with gold nanoparticles (Au-mPEG(5000)-SH NPs) acting on diethylnitrosamine (DEN)-induced hepatocarcinogenesis in male Wistar albino rats was studied. DEN-administered animals exhibited increased mast cell counts, transcription factor nuclear factor-kB, tumor necrosis factor alpha, glycoconjugates, argyrophilic nucleolar organizing regions and proliferating cell nuclear antigen. While Au-mPEG(5000)-SH NPs supplementation efficiently suppressed all the observed abnormalities. These results indicates that the Au-mPEG(5000)-SH NPs exhibited significant potential anticancer activity by suppressing cell inflammation and proliferation in DEN-induced hepatocellular carcinogenesis [24]. Similarly, hesperetin at concentration of 20 mg/kg BW, inhibited cell proliferation markers, COX-2 mRNA expression, angiogenic growth factors, enhanced apoptosis, and reduced aberrant crypt foci in DMH-induced colon carcinogenesis in rats [25]. Western blot analysis indicated that cyclin D1, CDK4, and Bcl-XL were reduced in the tumors in breast cancer of hesperetin-treated mice, the results suggested that flavonone reduced plasma estrogen [26]. Hesperetin was also reported to modulate xenobiometric-metabolizing enzymes on DMH-induced colon carcinogenesis [27].

Rossi et al. provided case-control study and obtained important results in subgroups of population, in special for flavanones, and these data should be taken with caution as statistical results might not be sufficient to detect meaningful associations. Previously, no study investigated the relation between flavonones and endometrial cancer risk, in respect of their estrogenic and anti-estrogenic activity [28].

This section highlighted that hesperidin and hesperetin have potent effects against different types of cancers. As our interest is on bladder cancer, the next sections present and discuss the recent progress on the uses chemotherapeutic regimens to combat bladder cancer and the potent uses of hesperidin and hesperetin against bladder cancer.

Bladder Cancer

The standard of care for bladder cancer has presented just a few changes over the last decades and treatment options remain limited. Some treatments, such as cystectomy, imply drastic lifestyle changes that diminish the patients’ quality of life while falling far short of achieving cure. The standard conservative treatments surgical resection of urinary bladder followed by intravesical Bacillus Calmette-Guerin (BCG) immunotherapy prevent the progression of high-grade non-muscle invasive bladder cancer (NMIBC) to advanced disease. But, often the efficacy is weakened by the emergence of refractory or relapsing disease, and toxicity causes the discontinuation of the treatment. Radical or partial cystectomy is the option for non-responsive patients to the current bladder-sparing therapies.
Patients who refuse or are not eligible for bladder removal face a dismal prognosis, due to the increased risk of progression to advanced disease. Despite conservative treatments, a large number of NMIBC patients at the time of diagnosis will develop invasive or metastatic disease. Around half of patients with specific advanced or metastatic bladder cancer do not respond satisfactorily to first-line platinum-based chemotherapies, that is, methotrexate, vinblastine, doxorubicin (adriamycin) and cisplatin (MVAC), and gemcitabine and cisplatin (GC) (Figure 2).

Due to cisplatin’s high toxicity, many patients will receive doses lower than those typically recommended or even no treatment. The alternative would be a carboplatin-based chemotherapy, as second-line treatment (gemcitabine plus carboplatin or gemcitabine plus paclitaxel), which provides a median survival of 9-10 months [29]. Despite the first-line platinum-based therapy, options are quite few for those patients whose malignant lesions progress. Only 10% to 15% of them respond to second-line single-agent chemotherapy [29].

It is known from the literature that many of the anticancer drugs are very toxic and the role of the flavonoids might be important to ameliorate their toxicity. For example, doxorubicin (DOX) is one of the effective cytotoxic drugs applied in cancer therapy, but, cumulative cardiotoxicity and nephrotoxicity confines its clinical applications. Systemic application of drugs given by intravesical therapy mostly reach the inner part of the bladder, with little-to-no effect on other organs, such as the liver, heart, lung, spleen, kidneys, ureters, and urethra. It is known that intravesical chemotherapy can maximize the exposure of tumor to any therapeutic agents while limit the drug systemic toxicity due to the lumen structure of the bladder. For example, nanoparticles prepared with cationic 1,2-dioleoyl-3-trimethylammonium propane/methoxypoly (ethylene glycol) (DPP) to give up doxorubicin (DOX) for intravesical administration of bladder cancer were studied. The DPP micelles were able to extend the residence of DOX in the bladder, increase the penetration of DOX into the bladder wall, and enhance cellular uptake of DOX. DOX encapsulation by DPP micelles extensively improved the in vivo anticancer effect of DOX against orthotopic bladder cancer [30].

Cisplatin (CIS) is the main player in chemotherapy of muscle invasive urinary bladder cancer (MIBC). CIS as monotherapy in MIBC is considerate as less efficient than associated therapy. CIS is also considered a Gold standard following the data of the randomized prospective trials and too in a major meta-analysis of all randomized controlled trials addressing the concept (RCTs). Basic immunomodulatory effects of CIS are:

- Raised the major histocompatibility complex (MHC) class I expression, which is important for tumor cell recognition and deletion by CD8+ cytotoxic T cells, and enhanced expression would thus therefore promote anti-tumor immune responses.
- Enrollment and proliferation of effectors’ cells is of essential importance for an efficient immune response to happen. Experimental investigations indicate CIS as a facilitator and promoter in the homing process leadings substantially increased amounts of activated cytotoxic T cells (CTLs), both systematically and locally in the tumor.
- Increase of tumor-lytic activity of cytotoxic effectors. A previous treatment of CTLs with CIS has been shown to enhance CTL-mediated killing of tumor cells in cells lines, such as lymphoblastoid cell lines and in other cells.
- Down regulation of immunosuppressive agents in the microenvironment. CIS has been demonstrated to down regulate either myeloid-derived suppressor cells (MDSC) and T regulatory cells (Treg) in different studies, with suggested secondary effects on immunocompetent cells being unobstructed in their respective activity. Data indicate that CIS has a function of revealing and exhibiting subdominant epitopes of tumor antigens. Thereby, increasing the possibility of the adaptive immune system (CTLs) to recognize else hidden tumor targets [31].

Unfortunately, CIS exerts many side effects (occurring in greater than 30%) for patients: nausea and vomiting, kidney toxicity, ototoxicity, low blood counts and blood test abnormalities. The side effects that occur in 10%-29% for patients receiving CIS are peripheral neuropathy, taste changes, loss of appetite, hematological problems and hair loss (http://chemocare.com/chemotherapy/ drug-info/cisplatin.aspx). CIS treatment also can lead to significant reduction on the enzymatic activity of antioxidant enzymes like SOD, glutathione peroxidase (GPx), catalase (CAT), glutathione S-transferases (GST) and glutathione reductase (GR).

**Potential Effects of Hesperidin and Hesperetin and other Flavonoids on Cancer**

This section highlights the beneficial effects of hesperidin and hesperetin associated with traditional chemotherapeutic drugs in different cancers.

Abdel-Raheem and Abdel-Ghany in 2009 studied the protective effect of hesperidin against cardiotoxicity in rats by DOX treatment [32]. Imbalance in nitric oxide (NO) generation and increased ROS have been implicated in the cardiotoxicity of doxorubicin. The results demonstrated significant decrease in glutathione (GSH) levels, superoxide dismutase (SOD) activity, and enhance in thiobarbituric acid reactive substances (TBARS) levels, showing that doxorubicin-induced cardiotoxicity was mediated through reactive oxygen species (ROS) generation. These findings disclose pretreatment with hesperidin reversed negative effects induced by DOX [33].

Hesperidin diminished CIS-induced functional and histopathological liver damage in a dose-dependent manner non-affecting its potential cytotoxic effect [34]. Hesperidin application...
produced a potent protection against CIS alterations in antioxidant enzymes levels by turning them to normal. But, a low dose of hesperidin was unfruitful to exert any consequential raise in GR and CAT activities [35].

Hesperidin’s nephroprotective activity was assessed in male Albino rats after intraperitoneal administration of CIS. CIS nephrotoxicity was demonstrated by elevated levels of blood urea nitrogen, high protein excretion in urine, serum creatinine, and reduced levels of creatinine clearance. Then, hesperidin made a significant protection against cisplatin-induced nephrotoxicity in a dose dependent manner [36].

Kumar et al. studied the protective effect of hesperidin to myocardial injury induced by cyclophosphamide (CP) [37]. CP described an important increased level of malonaldehyde (MDA) and reciprocally decreased levels of SOD, GPx, CAT, GSH and GST in cardiac tissue. Hesperidin group showed elevated levels of all cited enzymes and a diminished level of MDA. Similar results with CP were previously published [38].

In addition, another flavonoid, apigenin (API) acts also synergizing the effect with chemotherapeutic agents such as gemcitabine and 5-fluorouracil in vivo [39,40]. This fact might indicate that hesperidin and/or hesperetin could act in the same direction. Also, quercetin has the capability to reduce the corneal opacity caused by corneal edema that inhibits mitomycin C (MMC)-induced damage to the corneal endothelial cells [40]. Oral administration of diosmine and quercetin was studied on hematological and hepatic toxicity of a single dose of CP or vinblastine on rats’ female albino’s Wistar. In the group of rats treated only with the CP, since the 1st day, it was observed an increase of lipid peroxide (MDA) more than once (120%) and a decay of hepatic glutathione and enclosing the group receiving the vinblastine (until more than two times of reduction - 120%). Also, a severe leucopenia and thrombopenia were noted between the 3rd and the 14th days at rats treated by the chemotherapeutic agents alone (CP and vinblastine) [40].

The association of flavonoids with drugs has efficiently reduced the effect of drugs’ toxicity. Actually, the aplastic observed with the vinblastine, as well as the leucopenia and thrombopenia of the CP were totally corrected. Similarly, the authors observed a restoration of rates of peroxide and GSH. They suggested that flavonoids seem to act by activation of the turnover of the GSH and enzymes stimulating particularly glutathione S-transferases letting the sequestration of the reactive metabolites of the drugs under studying [41].

Choi et al. demonstrated that the pre-treatment with flavonoids, such as quercetin, acting on male SD rats increased the bioavailability of paclitaxel or its water-soluble pro-drug [42]. Moreover, the co-administration with flavones produced a significant increase of the bioavailability of this drug and they suggest that this probably occurred through the inhibition of P-gp or CYP3A [43]. Similar results were demonstrated by altering the pharmacokinetics of paclitaxel by a concomitant use of morin (flavonoid) in rats [44].

A study with apigenin was projected to investigate whether combined therapy with apigenin and gemcitabine enhanced anti-tumor activity in pancreatic cancer. In studies in vitro, the combined treatment significantly suppressed cell growth and apoptosis through the down-regulation of NF-κB activity with inhibition of Akt activation in pancreatic cancer cell lines, such as MiaPaca-2 and AsPC-1. In the case of in vivo treatment, the combined therapy augmented tumor growth suppressed through the down-regulation of NF-κB activity with the inhibition of Akt in tumor tissue. The association of apigenin and gemcitabine increased anti-tumor efficacy through Akt and NF-κB activity inhibition and apoptosis induction [45].

In a pre-treatment with hesperetin on rats with DMBA-induced mammary gland tumors, significantly diminished the tumor burden and the over-expression of the proliferating cell nuclear antigen (PCNA), even as, recovering the decreased Bcl-2 and increased Bax expression. On the contrary, in the liver of mice previously treated with DMBA, the hesperetin application prevented DNA fragmentation, cleaved caspase-3, caspase-9 and PARP, and decreased Bax expression [46]. This study indicates that hesperetin may act as a pro-apoptotic or anti-apoptotic agent depending on the situation [46]. Daily administration of hesperetin for fifteen weeks suppressed rat colon carcinogenesis during and hereafter DMH initiation [27].

Novel flavonoid - Oncamex demonstrated a strong antioxidant effect in breast cancer cell line through the induction of apoptosis and cytotoxicity. In the MCF-7 cells treatment with Oncamex were tracked after 24 h and 72 h and showed substantial changes in depletion of cell density and division, nuclear morphology and arising of apoptotic cells. After 72 h of treatment, abundant apoptotic, phagocytized and dead cells were present. Further investigation of Oncamex’s mechanism demonstrated that treatment of MCF-7, MDAMB-231, BT-549 and HBL-100 cells with micromolar concentrations for 8 h induced dose-dependent, inversely correlated changes with cell viability and cytotoxicity, along with caspase-3/-7 activation, consistent with apoptosis [47].

Perspectives of Flavonoids with Emphases on Hesperidin and Hesperetin from Orange Peels or Juice on Bladder Cancer

The chemopreventive effects of diosmine and hesperidin, on N-butyl-N-(4-hydroxybutyl) nitrosamine (OHBNN)-induced urinary-bladder carcinogenesis in male ICR mice were verified. The applications of the both compounds, isolated or in combination, in the treatment caused an important reduction in the frequency of bladder carcinoma and pre-neoplasia. Orally administration of diosmin and hesperidin significantly decreased the silver-stained-nucleolar-organizer-region-associated proteins (AgNOR) count and the 5-bromodeoxyuridine (BUDR)-labeling index of several bladder lesions. These observations suggest that diosmin and hesperidin, individually and in association, are effective in suppressing chemical carcinogenesis of the bladder, and that such suppression might be partly related to inhibition of cell proliferation [48].

Many different meta-analyses have discussed an inverse association between citrus fruits intake and the risk of several types of cancers, and among them bladder cancers [49-52]. This is explainable since the most abundant citrus flavonoid is hesperidin [53]. The orange hesperidin content is 28-42 mg/g of dry peel and 12-44 mg/g of waste from orange juice [54]. It is known that the beneficial effects of flavonoids are due to their anti-oxidant properties, which are a key role in fighting several degenerative diseases. Meanwhile, there is recent enhancing evidence linking the pharmacological activity of Citrus flavonoids to their capability to inhibit the activity of intracellular signaling molecules, such as kinases, phosphodiesterases, topoisomerases, and other different regulatory enzymes [55,56].

Table I lists recent studies of bioflavonoids and their antiproliferative and anti-cancer activity in bladder cancer treatment. Bioflavonoids mentioned in the table have very similar structure to hesperidin and hesperetin and belong to other flavonoid subclasses.
Conclusions and Final Remarks

Since hesperidin acts directly in the bladder cancer, as stated and discussed in the previous sections, together with the strong indications that extracts of orange peels and orange juice may also show this anticancer activity, tackle the necessity of a detailed study on hesperidin or hesperetin benefits in bladder cancer treatments. One of the strategies would be to investigate hesperidin or hesperetin as co-adjutant of the chemotherapeutics regiment in bladder cancer (e.g., DOX, CIS, MMC, etc.). Perspectives of this research might be great, if we joint our expertise in bladder cancer on animals (57-71) and easiness of obtaining hesperidin and hesperetin in our laboratories. At last bit not at least, this mini-review shows the importance of introducing new, nontoxic and economically feasible natural products for the cancer treatment.

Acknowledgement

Supports by FAPESP, INOMAT (MCTI/CNPq), NanoBios (MCTI/CNPq), and Citrusuco Company are kindly acknowledged.

References


Table 1: Natural bioflavonoids as a potential bladder cancer inhibitors and pro-drugs.

<table>
<thead>
<tr>
<th>Source</th>
<th>Flavonoid</th>
<th>IC_{50}</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cranberry flavonoids</td>
<td>Quercetin-3-O-glucoside</td>
<td>8-92 µM</td>
<td>[57]</td>
</tr>
<tr>
<td></td>
<td>3’-O-methylquercetin (isorhamnetin)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Quercetin</td>
<td>40-70 µM</td>
<td>[58]</td>
</tr>
<tr>
<td>Aladdin chemistry Co. Ltd</td>
<td>Baicalein, baicalin and wogonin</td>
<td>3.4-100 µM</td>
<td>[59]</td>
</tr>
<tr>
<td>Scutellariae radix</td>
<td>Myricetin</td>
<td>20-100 µM</td>
<td>[60]</td>
</tr>
<tr>
<td>Gosun Biotecnology Co.</td>
<td>Fisetin</td>
<td>60-100 µM</td>
<td>[61]</td>
</tr>
<tr>
<td>Sigma Aldrich</td>
<td>Flavokawain</td>
<td>25-62 µM</td>
<td>[62]</td>
</tr>
<tr>
<td>Kava Extract</td>
<td>Proanthocyanidin</td>
<td>25-50 µM</td>
<td>[63]</td>
</tr>
</tbody>
</table>


